Nicole Toursarkissian

Safety, immunogenicity, and lot-to-lot consistency of a split-virion quadrivalent influenza vaccine in younger and older adults: A phase III randomized, double-blind clinical trial

P. van Damme, G. Leroux-Roels, Sanie S S Sesay, 2017, Human vaccines & immunotherapeutics.

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

P. Gosse, S. Oparil, Pankaj Gupta, 2022, The Lancet.

The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70

A. Schaefer, Shinn-Jang Hwang, G. Icardi, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Persistence of Immune Response to an Adjuvanted Varicella‐Zoster Virus Subunit Candidate Vaccine for up to Year 9 in Older Adults

T. Schwarz, L. Rombo, M. David, 2017, Open Forum Infectious Diseases.

Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination

Hyo Youl Kim, Kenjiro Nakamura, A. Schaefer, 2022, Open forum infectious diseases.

Transiently achieved very low low-density lipoprotein cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Pedro F. Campos, Luciano Lopes de Sousa, Howard D. Rubenstein, 2023, European heart journal.

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

H. Huikuri, H. Suryapranata, A. Bagai, 2024, European heart journal. Cardiovascular pharmacotherapy.